Kyntra Bio (KYNB) Non-Current Debt (2023 - 2026)
Kyntra Bio (KYNB) posted Non-Current Debt of $73.4 million for Q1 2025, little changed sequentially from $73.1 million in Q4 2024, and up 1.67% YoY from $72.2 million in Q1 2024.
Kyntra Bio (KYNB) Non-Current Debt (2023 - 2026) Analysis & Trends
Kyntra Bio has reported Non-Current Debt for 3 years, with the latest figure at $73.4 million in Q1 2025.
- Quarterly Non-Current Debt rose 1.67% year-over-year to $73.4 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $73.4 million (up 1.67% YoY) and the FY2024 annual result came in at $73.1 million, up 1.61% from the prior year.
- Non-Current Debt steadied at $73.4 million in Q1 2025 per KYNB's latest filing, from $73.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $73.4 million in Q1 2025 and troughed at $71.4 million in Q2 2023.
- A 3-year average of $72.4 million and a median of $72.3 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt advanced 1.5% in 2024, then advanced 1.67% in 2025.
- Over 3 years, Non-Current Debt stood at $71.9 million in 2023, then climbed by 1.61% to $73.1 million in 2024, then increased by 0.45% to $73.4 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $73.4 million, $73.1 million, and $72.8 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 8.96 Bn |
| 10 | Kyntra Bio | 30.32 Mn | 30.32 Mn | 1.47 Mn | 19.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.20 Mn |
| Mar 31, 2025 | 73.42 Mn |
| Dec 31, 2024 | 73.09 Mn |
| Sep 30, 2024 | 72.78 Mn |
| Jun 30, 2024 | 72.48 Mn |
| Mar 31, 2024 | 72.21 Mn |
| Dec 31, 2023 | 71.93 Mn |
| Sep 30, 2023 | 71.67 Mn |
| Jun 30, 2023 | 71.41 Mn |